Haemonetics Announces Sale of Whole Blood Assets to GVS, S.p.A
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/29/2026
- Stocks fall as higher oil prices, Treasury yields weigh
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- MongoDB stock drops 15% as CEO Desai resigns for Meta
- Jefferies cuts Roblox to Underperform, says rally is too optimistic
BTIG Reiterates Buy Rating on Haemonetics (HAE)
December 3, 2024 7:38 AM ESTBTIG analyst Marie Thibault reiterated a Buy rating and $112.00 price target on Haemonetics (NYSE: HAE).
The analyst comments "Earlier this morning, Haemonetics announced that it would be selling its Whole Blood assets to GVS, S.p.A (GVS.MI, Not Rated). This does not come as a surprise since HAE has been vocal about its ongoing efforts to rationalize the Whole... More
